Methods and vaccines for inducing immune responses to multiple different MHC molecules
AssigneesMayo Foundation for Medical Education and Research, University of Washington
InventorsDustin B. McCurry, Peter A. Cohen, Latha B. Pathangey, Sandra J. Gendler, Mary L Disis
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials relating to isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, polypeptides (e.g., CMV, MUC1, HER2, Mesothelin (MESO), TRAG-3, or CALR polypeptides) having the ability to be processed into different polypeptides such that the processed polypeptides as a group are capable of being presented by different MHC molecules present in a particular mammalian population are provided.
Claims32
An isolated polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said polypeptide is amidated at the C-terminus.
An isolated polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said polypeptide is acetylated at the N-terminus.
A composition comprising at least one isolated polypeptide and an adjuvant, wherein the amino acid sequence of said at least one polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, MF59, Pam3CSK4, LPS, polyIC, imiquimod, or R848.
A method of treating cancer or a precancerous condition in a mammal, wherein said method comprises administering to said mammal a composition comprising an adjuvant and at least one polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, or MF59.
A vaccine comprising an adjuvant and at least one polypeptide, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, and wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, or MF59.
A method of inducing an immune response against at least one polypeptide, wherein the sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58, wherein said method comprises administering a composition comprising said polypeptide and an adjuvant to a mammal in an amount effective to induce an immune response against said polypeptide, wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, or MF59.
A method of treating cancer or a precancerous condition in a mammal, wherein said method comprises contacting T-cells obtained from said mammal with at least one polypeptide set forth in any one of SEQ ID NOs:1-58 to activate said T-cells, and administering said activated T-cells to said mammal.
A method of treating cancer or a precancerous condition in a mammal, wherein said method comprises administering activated T-cells to said mammal, wherein said activated T-cells are T-cells that were obtained from said mammal and contacted with at least one polypeptide to activate said T-cells, wherein the amino acid sequence of said polypeptide is as set forth in any one of SEQ ID NOs:1-58.
Dependencies are inferred from the claim text.